학술논문

The liver fibroinflammatory marker cT1 is reduced with aldafermin therapy in a randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis
Document Type
Journal
Source
JOURNAL OF HEPATOLOGY; JUL 2021, 75 pS410-pS415, 6p. Supplement: 2
Subject
Language
English
ISSN
16000641